Prof. Dr. Gerd Bendas

Pharmazeutisches Institut
Pharmazeutische und zellbiologische Chemie
An der Immenburg 4
53121 Bonn
Fon: +49-228-73-5250
Fax: +49-228-73-4692
Mail: [Email protection active, please enable JavaScript.]

« Mai 2020 »
Mo Di Mi Do Fr Sa So
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31
Sie sind hier: Startseite Publikationen



Publikationen ab 2001 
Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G.

Beta1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters.
Biochim Biophys Acta Mol Cell Res. (2020)

Wantoch von Rekowski K, König P, Henze S, Schlesinger M, Zawierucha P, Januchowski R,  Bendas G.

The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.
Biomolecules (2019)

Jakubzig B*, Baltes F*, Henze S, Schlesinger M, Bendas G. (* geteilte Erstautorenschaft / equally contributed)

Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells - Deciphering Novel Potential Targets for a Cell Sensitization.
Cancers (Basel) 10 (2018)

Gockel LM*, Ponert JM*, Schwarz S, Schlesinger M, Bendas G. (* geteilte Erstautorenschaft / equally contributed)

The Low Molecular Weight Heparin Tinzaparin Attenuates Platelet Activation in Terms of Metastatic Niche Formation by Coagulation-Dependent and Independent Pathways.
Mol Basel Switz 23 (2018)

Ponert JM, Gockel LM, Henze S, Schlesinger M.

Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells.
Mol Basel Switz 23 (2018)

Schlesinger, M

Role of platelets and platelet receptors in cancer metastasis.
J Hematol Oncol 11 (2018) 125

von Bargen K, Scraba M, Krämer I, Ketterer M, Nehls C, Krokowski S, Repnik U, Wittlich M, Maaser A, Zapka P, Bunge M, Schlesinger M, Huth G, Klees A, Hansen P, Jeschke A, Bendas G, Utermöhlen O, Griffiths G, Gutsmann T, et al.

VapA from Rhodococcus equi is an inter-compartmental pH-neutralising virulence factor.
Cell Microbiol e12958 (2018)

Hoß SG, Grundmann M, Benkel T, Gockel L, Schwarz S, Kostenis E, Schlesinger M, Ilan N, Vlodavsky I, Bendas G.

Pro-Angiogenic Effects of Latent Heparanase and Thrombin Receptor-Mediated Pathways-Do They Share a Common Ground in Melanoma Cells?
Thromb Haemost 118 (2018) 1803–14

Ponert JM, Schwarz S, Haschemi R, Müller J, Pötzsch B, Bendas G. Schlesinger, M

The mechanisms how heparin affects the tumor cell induced VEGF and chemokine release from platelets to attenuate the early metastatic niche formation.
PLoS One. 13(1) (2018)

Piva MBR*, Jakubzig B*, Bendas G. (* geteilte Erstautorenschaft / equally contributed)
Integrin Activation Contributes to Lower Cisplatin Sensitivity in MV3 Melanoma Cells by Inducing the Wnt Signalling Pathway.
Cancers (Basel). 9 (2017)

Pfankuchen DB, Baltes F, Batool T, Li JP, Schlesinger M, Bendas G.
Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway.
Oncotarget. 8 (2017)

Ross T*, Jakubzig B*, Grundmann M, Massing U, Kostenis E, Schlesinger M,, Bendas G. (* geteilte Erstautorenschaft / equally contributed)
The molecular mechanism by which saturated lysophosphatidylcholine attenuates the metastatic capacity of melanoma cells.
FEBS Open Bio. 6 (2016)

Mueller T., Pfankuchen DB., Wantoch von Rekowski K., Schlesinger M., Reipsch F., Bendas G.
The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Molecules 22 (2017) 5.

Hoß SG, Bendas G.
Mass-Sensitive Biosensor Systems to Determine the Membrane Interaction of Analytes.
Methods Mol Biol. (2017)

Hoß S, Schlesinger M., Bendas G.
The matricellular ligand Cyr61 contributes to the metastatic spread of tumors by activating integrin VLA-4, independently of thiol redox modulation.
Int J Clin Pharmacol Ther. (2016) [Epub ahead of print].

Bisht S., Schlesinger M., Rupp A., Schubert R., Nolting J., Wenzel J., Holdenrieder S., Brossart P., Bendas G., Feldmann G.
A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
J Nanobiotechnology. 14 (2016) 57.

Roblek M., Calin M., Schlesinger M., Stan D., Zeisig R., Simionescu M., Bendas G., Borsig L.
Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis.
J Control Release Soc. 28 (2015) 341–7.

Ross T., Heuter S., Schlesinger M., Jakubzig B., Raynor A., Massing U.,  Bendas G.
Lysophosphatidylcholine attenuates melanoma cell adhesion and migration dependent on the degree of fatty acid saturation.
Int J Clin Pharmacol Ther. 53 (2015)1049–51.

Schlesinger M., Zeisig R., Ortmann K., Calin M., Gerber U., Roblek M., Borsig L., Bendas G.
Inhibition of chemokine receptor CCR2 reduces sarcoma cell transendothelial migration and metastasis to the lungs.
Int J Clin Pharmacol Ther. 53 (2015) 1046-8.

Pfankuchen DB., Stölting DP., Schlesinger M., Royer HD., Bendas G.
Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
Biochem Pharmacol. 97 (2015) 147-57.

Raynor A., Jantscheff P., Ross T., Schlesinger M., Wilde M., Haasis S., Dreckmann T., Bendas G.

Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases.
Lipids Health Dis. 14 (2015) 69.

Gerber U., Hoß SG., Shteingauz A., Jüngel E., Jakubzig B., Ilan N., Blaheta R., Schlesinger M., Vlodavsky I., Bendas G.
Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
Semin Thromb Hemost. 41 (2015) 244–54.

Calin M., Stan D., Schlesinger M., Simion V., Deleanu M., Constantinescu CA., Gan AM., Pirvulescu MM., Butoi E., Mandateanu I., Bota M., Enachescu M., Borsig L., Bendas G., Simionescu M.
VCAM-1 directed target-sensitive liposomes carrying CCR2 antagonists bind to activated endothelium and reduce adhesion and transmigration of monocytes.
Eur J Pharm Biopharm
. 89 (2015) 18–29.

Münch D., Engels I., Müller A., Reder-Christ K., Falkenstein-Paul H., Bierbaum G., Grein F., Bendas G., Sahl HG., Schneider T.
Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin.
Antimicrob Agents Chemother.
59 (2015) 772–81.

Schütte U., Bisht S., Heukamp LC., Kebschull M., Florin A., Haarmann J., Hoffmann P., Bendas G., Buettner R., Brossart P., Feldmann G.

Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.
Transl Oncol. 7 (2014) 309-21.

Schlesinger M., Roblek M., Ortmann K., Naggi A., Torri G., Borsig L., Bendas G.
The role of VLA-4 binding for experimental melanoma metastasis and its inhibition by heparin.
Thromb Res. 133 (2014) 855-62.

Stölting DP, Borrmann M, Koch M, Wiese M, Royer HD, Bendas G.
How liposomal Cisplatin overcomes chemoresistance in ovarian tumour cells.
Anticancer Res. 34 (2014) 525-30.

Stölting DP., Koch M., Wiese M., Royer HD., Bendas G.
Liposomal cisplatin can overcome chemotherapy resistance of A2780 ovarian cancer cells by inducing the extrinsic apoptotic pathway.
Int J Clin Pharmacol Ther. 52 (2013) 78-81.

Reder-Christ K., Schmitz P., Bota M., Gerber U., Falkenstein-Paul H., Fuss C., Enachescu M., Bendas G.
A dry membrane protection technique to allow surface acoustic wave biosensor measurements of biological model membrane approaches.
Sensors (Basel). 13 (2013) 12392-12405.

Schmitz P., Gerber U., Schütze N., Jüngel E., Blaheta R., Naggi A., Torri G., Bendas G.
Cyr61 is a target for heparin in reducing MV3 melanoma cell adhesion and migration via the integrin VLA-4.
Thromb Haemost. 110 (2013) 1046-1054.

Meschenmoser K., Kim Y., Franken S., Nowak M., Feldmann G., Bendas G., Wolfgarten M., Messmer D., Schmidt-Wolf IG.
Targeting cancer with a bi-functional peptide: in vitro and in vivo results.
In Vivo. 27 (2013) 431-442.

Koch M., Krieger ML., Stölting D., Brenner N., Beier M., Jaehde U., Wiese M., Royer HD., Bendas G.
Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: molecular mechanisms unveiled by gene expression profiling.
Biochem Pharmacol. 85 (2013) 1077-1090.

Stölting DP., Jaehde U., Wiese M., Bendas G.
Are low molecular weight heparins able to sensitize chemoresistant tumor cells?
Int J Clin Pharmacol Ther. 51 (2013) 70-73.

Schmitz P., Gerber U., Jüngel E., Schütze N., Blaheta R., Bendas G.
Cyr61/CCN1 affects the integrin-mediated migration of prostate cancer cells (PC-3) in vitro.
Int J Clin Pharmacol Ther. 51 (2013) 47-50.

Schneider V., Krieger ML., Bendas G., Jaehde U., Kalayda GV.
Contribution of intracellular ATP to cisplatin resistance of tumor cells.
J Biol Inorg Chem. 18 (2013) 165-74.

Müller A., Münch D., Schmidt Y., Reder-Christ K., Schiffer G., Bendas G., Gross H., Sahl H.G., Schneider T., Brötz-Oesterhelt H.
The lipodepsipeptide empedopeptin inhibits cell wall biosynthesis through Ca2+-dependent complex formation with peptidoglycan precursors.
J Biol Chem. 2012 Apr 18. [Epub ahead of print]

Schlesinger M, Schmitz P, Zeisig R, Naggi A, Torri G, Casu B, Bendas G.
The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
Thromb Res. 5 (2012) 603-10.

Reder-Christ K, Schmidt Y, Dörr M, Sahl HG, Josten M, Raaijmakers JM, Gross H, Bendas G.
Model membrane studies for characterization of different antibiotic activities of lipopeptides from Pseudomonas.
Biochim Biophys Acta. 3 (2012), 566-73.

Jantscheff P., Schlesinger M., Fritzsche J., Taylor L.A., Graeser R., Kirfel G., Fürst D.O., Massing U., Bendas G. Lysophosphatidylcholine Pretreatment Reduces VLA-4 and P-Selectin–Mediated B16.F10 Melanoma Cell Adhesion In vitro and Inhibits Metastasis-Like Lung Invasion In vivo.
Mol Cancer Ther 10 (2011), 186-197.

Reder-Christ K, Falkenstein-Paul H, Klocek G, Al-Kaddah S, Bakowsky U, Bendas G.
Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin.
Int J Antimicrob Agents. 37 (2011), 256-60.

Al-Kaddah S., Reder-Christ K., Klocek G., Wiedemann I., Brunschweiger M., Bendas G.
Analysis of membrane interactions of antibiotic peptides using ITC and biosensor measurements.
Biophys. Chem. 152 (2010), 145-152.

Alexander M., Schlesinger M., Jantscheff P., Massing U., Bendas G.
Reduction in human melanoma cell adhesion receptor activity by lysophosphatidylcholine (LPC) treatment - functional characterization and signal pathway analyses.
Int. J. Clin. Pharmacol. Ther. 48 (2010), 478-480.

Schneider V., Kalayda G.V., Krieger M.L., Bendas G., Jaehde U.
Intracellular ATP depletion leads to reduced platinum accumulation in ovarian cancer cells.
Int. J. Clin. Pharmacol. Ther. 48 (2010), 456-458.

Schlesinger M., Naggi A., Torri G., Zeisig R., Alexander M., Schmitz P., Casu B., Bendas G.
Blocking of integrin-mediated human MV3 melanoma cell binding by commercial and modified heparins.
Int. J. Clin. Pharmacol. Ther. 48 (2010),448-450.

Krieger M.L., Konold A., Wiese M., Jaehde U., Bendas G.
Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells.
Int. J. Clin. Pharmacol. Ther. 48 (2010),442-444.

Linnemann, A., van der Ven, P.F., Vakeel, P., Albinus, B., Simonis, D., Bendas, G., Schenk, J.A., Micheel, B., Kley, R.A., Fürst, D.O.
The sarcomeric Z-disc component myopodin is a multiadapter protein that interacts with filamin and alpha-actinin.
Eur J CellBiol. 89 (2010), 681-692.

Simonis, D., Schlesinger, M., Seelandt, C., Borsig, L., Bendas, G.
Analysis of SM4 sulfatide as a P-Selectin ligand using model membranes.
Biophys. Chem. 150 (2010), 98-104.

Krieger, M.L., Eckstein, N., Schneider, V., Koch, M., Royer, H.D., Jaehde, U., Bendas, G.
Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro.
Int. J. Pharm. 389 (2010), 10-17.

Bendas, G.
Biosensor-based evaluation of liposomal binding behaviour.
Methods Mol. Biol. 606 (2009), 519-529.

Schlesinger, M., Simonis, D., Schmitz, P., Fritzsche, J., Bendas, G.
Binding between heparin and the integrin VLA-4.
Thromb. Haemost. 102 (2009), 816-822.

Alban, S., Ludwig, R.J., Bendas, G., Schön, M.P., Oostingh, G.J., Radeke, H.H., Fritzsche, J., Pfeilschifter, J., Kaufmann, R., Boehncke, W.H.
PS3, a semisynthetic beta-1,3-glucan sulfate, diminishes contact hypersensitivity responses through inhibition of L- and P-Selectin functions.
J. Invest. Dermatol. 129 (2009), 1192-1202.

Fritzsche, J., Simonis, D., Bendas, G.
Melanoma cell adhesion can be blocked by heparin in vitro: suggestion of VLA-4 as a novel target for antimetastatic approaches.
Thromb. Haemost. 100 (2008), 1166-1175.

Gege, C., Schumacher, G., Rothe, U., Schmidt, R.R., Bendas, G.
Visualization of the sialyl Lewis(X) glycosphingolipid microdomains in model membranes as selectin recognition motifs using a fluorescence label.
Carbohydr. Res. 343 (2008), 2361-2368.

Christ, K., Al-Kaddah, S., Wiedemann, I., Rattay, B., Sahl, H.G., Bendas, G.
Membrane lipids determine the antibiotic activity of the lantibiotic gallidermin
J. Membr. Biol. 226 (2008), 9-16.

Gosk, S., Moos, T., Gottstein, C., Bendas, G.
VCAM-1 directed immunoliposomes selectively target tumour vasculature in vivo.
Biochim. Biopys. Acta 1778 (2008), 854-863.

Höpfner, M., Rothe, U., Bendas, G.
A biosensor-based evaluation of the liposomal behaviour in the target binding process.
J. Liposome Res. 18 (2008), 71-82.

Christ, K., Wiedemann, I., Bakowsky, U., Sahl, H.G., Bendas,G.
The role of lipid II in membrane binding of and pore formation by nisin analyzed by two combined biosensor techniques.
Biochim. Biophys. Acta 1768 (2007), 694-704.

Simonis, D., Christ, K., Alban, S., Bendas, G.
Affinity and kinetics of different heparines binding to P- and L-Selectin.
Sem. Thromb. Hemost. 33 (2007), 534-539.

Bakowsky, H., Richter, T., Kneuer, C., Hoekstra, D., Rothe, U., Bendas, G., Ehrhardt, C., Bakowsky, U.
Adhesion characteristics and stability assessment of lectin-modified liposomes for site-specific drug delivery.
Biochim. Biophys. Acta 1778 (2007), 242-249.

Simonis, D., Fritzsche, J., Alban, S., Bendas, G.
Kinetic analysis of heparin and glucan sulfates binding to P-Selectin and its impact on the general understanding of selectin inhibition.
Biochemistry 46 (2007), 6156-6164.

Schumacher, G., Bakowsky, U., Gege, C., Schmidt, R.R., Rothe, U., Bendas, G.
Lessons learned from clustering of fluorinated glycolipids on selectin ligand function in cell rolling.
Biochemistry 45 (2006), 2894-2903

Fritzsche, J., Alban, S., Ludwig. R., Boehncke, W.H., Schumacher, G., Bendas, G.
The influence of structural parameters affecting the P-Selectin binding of semisynthetic sulfated polysaccharides.
J. Biochem. Pharmacol. 72 (2006), 474-485.

Schumacher, G., Bendas, G., Stahl, B., Beermann, C.
Human milk oligosaccharides affect P-Selectin binding activity: in vitro investigations.
Nutrition 6 (2006), 620-627.

Christ, K., Rüttinger, H.H., Höpfner, M., Rothe, U., Bendas, G.
The detection of UV-induced membrane damages by a combination of two biosensor techniques.
Photochem. Photobiol. 81 (2005), 1417-1423.

Fritzsche, J., Hünerbein, I., Schumacher, G., Alban, S., Ludwig, R., Gille, J., Bendas, G.
In vitro-investigation on the selectin binding mechanisms in tumor cell metastasis and their inhibition by heparin.
Int. J. Clin. Pharmacol. Therap. 43 (2005), 570-572.

Gosk, S., Gottstein, C., Bendas, G.
Targeting of immunoliposomes to VCAM-expressing endothelial cells, a future strategy in cancer therapy.
Int. J. Clin. Pharmacol. Therap. 43 (2005), 581-582.

Bendas, G.
Inhibition of membrane receptors involved with leukocyte extravazation.
Mini Rev. Med. Chem. 5 (2005), 575-584.

Gege, C., Schneider, M., Schumacher, G., Limozin, L., Rothe, U., Bendas, G., Tanaka, M., Schmidt, R.R.
Functional microdomains of glycolipids with partially fluorinated membrane anchors: Impact in cell adhesion.
ChemPysChem. 5 (2004), 216-224.

Höpfner, M., Schumacher, G., Alban, S., Rothe, U., Bendas, G.
Selectin-blocking semisynthetic sulphated polysaccharides as promising anti-inflammatory agents.
J. Pharm. Pharmacol. 55 (2003), 697-706.

Bendas, G., Rothe, U., Scherphof, G.G., Kamps, J.A.A.M.
The influence of repeated injections on pharmakokinetics and biodistribution of different types of sterically stabilized immunoliposomes.
Biochim. Biophys. Acta 1609 (2003), 63-70.

Schumacher, G., Höpfner, M., Vogel, J., Bakowsky, U., Ikami, T., Rothe, U., Bendas, G.
Ein dynamisches Testsystem zur Untersuchung Selektin-inhibierender Substanzen als potentiell antiinflammatorische Verbindungen.
Pharmind 64 (2002), 808-815.

Bakowsky, U., Schumacher, G., Gege, C., Schmidt, R.R., Rothe, U., Bendas, G.
Cooperation between lateral ligand mobility and accessibility for receptor recognition in selectin-induced cell rolling.
Biochemistry 41 (2002), 4704-4712.

Bendas, G.
Untersuchung des Selektin-vermittelten Leukozytenrollens: Ein neuartiger Ansatz zur antiinflammatorischen Therapie.
BIOspektrum 7 (2001), 41-42

Bakowsky, U., Bendas, G., Rothe, U., Kneuer, C., Bakowsky, H., Hoeckstra, D.
Quartz crystal microbalance and AFM: Powerful tools for the characterization of specific interactions of lectin/PEG-modified liposomes with glycolipid bilayers.
J. Control. Rel. (2001), 5164-5165.

Bendas, G.
Immunoliposomes- A new approach to targeting cancer therapy.
BioDrugs 15 (2001), 215-224.

Kessner, S., Krause, A., Rothe, U., Bendas, G.
Investigation of the cellular uptake of E-selectin-targeted immunoliposomes by activated human endothelial cells.
Biochim. Biophys. Acta 1514 (2001), 177-190.

ausgewählte Publikationen vor 2001

Gege, C., Vogel, J., Bendas, G., Rothe, U., Schmidt, R.R.
Synthesis of the Sialyl Lewis X epitope attached to glycolipids with different core structures and their selectin-binding characteristics in a dynamic test system.
Chem. Eur. J. 6 (2000), 111-122.

Bendas, G., Krause, A., Bakowsky, U., Vogel, J., Rothe, U.
Targetability of novel immunoliposomes prepared by a new antibody conjugation technique.
Int. J. Pharm. 181 (1999), 79-93.

Vogel, J., Bendas, G., Bakowsky, U., Hummel, G., Schmidt, R.R., Kettmann, U., Rothe, U.
The role of glycolipids in mediating cell adhesion: A flow chamber study.
Biochim. Biophys. Acta 1372 (1998), 205-515.

Geyer, A., Reinhardt, S., Bendas, G., Rothe, U., Schmidt, R.R.
C2-symmetric Lewis antigen mimetics exhibiting the common structural motif.
J. Am. Chem. Soc. 119 (1997), 11707-11708.

Bendas, G., Vogel, J., Bakowsky, U., Krause, A., Müller, J., Rothe, U.
A Liposome-based model system for the stimulation of lectin-induced cell adhesion.
Biochim. Biophys. Acta 1325 (1997), 297-308.


Bendas G., Düfer M.
Update Biologicals: Rekombinante Proteine und ihr therapeutischer Einsatz.
1. Auflage 2016. Deutscher Apotheker Verlag, 85 S.
ISBN 978-3769266283

Schlesinger M., Bendas G.
Contribution of very late antigen-4 (VLA-4) integrin to cancer progression and metastasis.
Cancer Metastasis Rev. 34 (2015) 575-91

Schlesinger M., Bendas G.
Vascular cell adhesion molecule-1 (VCAM-1)-An increasing insight into its role in tumorigenicity and metastasis.
Int J Cancer. 136 (2015) 2504-14

Hartung A., Bendas G.
Half-Life Extension with Pharmaceutical Formulations: Liposomes.
in: Therapeutic Proteins - Strategies to Modulate their Plasma Half-Lives
ISBN 978-3-527-32849-9
Edited by R. Kontermann
Publisher: Wiley Backwell 2012, 299-314.

Bendas G, Borsig L.
Cancer cell adhesion and metastasis: Selectins, integrins and the inhibitory potential of heparins.
Int J Cell Biol. 2012; 2012: 676731doi:10.1155/2012/676731

Alexander M., Bendas G.
The Role of Adhesion Receptors in Melanoma Metastasis and Therapeutic Intervention Thereof Source.
in: Research on Melanoma - A Glimpse into Current Directions and Future Trends
ISBN 978-953-307-293-7
Edited by: Mandi Murph
Publisher: InTech, September 2011

Reder-Christ K., Bendas G.
Biosensor Applications in the Field of Antibiotic Research—A Review of Recent Developments.
Sensors 2011, 11, 9450-9466; doi:10.3390/s111009450